anti-CUB Domain Containing Protein 1 (CDCP1) Antibodies

Human CUB Domain Containing Protein 1 (CDCP1) interaction partners

1. CDCP1 knockdown reduced 3D invasion, which can be rescued by ACSL3 (show Acsl3 Antibodies) co-knockdown. In vivo, inhibiting CDCP1 activity with an engineered blocking fragment (extracellular portion of cleaved CDCP1) lead to increased LD abundance in primary tumors, decreased metastasis, and increased ACSL activity in two animal models of TNBC.

2. These results revealed that ADAM9 (show ADAM9 Antibodies) down-regulates miR-1 (show FSD1 Antibodies) via activating EGFR (show EGFR Antibodies) signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression.

3. CDCP1 is a novel marker of the most aggressive N-positive triple-negative breast cancers; CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival

4. High expression level of CDCP1 is associated with recurrence in glioblastoma.

5. These studies have important implications for the development of a therapeutic to block CDCP1 activity and Triple-negative breast cancer (TNBC)metastasis.

6. CDCP1 may facilitate loss of adhesion by promoting activation of EGFR (show EGFR Antibodies) and Src (show SRC Antibodies) at sites of cell-cell and cell-substratum contact.

7. Stromal expression patterns for both ADAM12 (show ADAM12 Antibodies) and CDCP1.

8. these data demonstrated that HIF-2alpha (show EPAS1 Antibodies) could promote hepatocellular carcinoma cell migration by regulating CDCP1

9. Our results establish that differential glycosylation, cell surface presentation and extracellular expression of CDCP1 are hallmarks of prostate cancer progression.

10. High CDCP1 expression is associated with Colorectal Cancer.

Mouse (Murine) CUB Domain Containing Protein 1 (CDCP1) interaction partners

1. Results indicate Cdcp1 (CD318) as a ligand of T-cell differentiation antigen CD6 (CD6 (show CD6 Antibodies)) and a potential target for the diagnosis and treatment of autoimmune diseases.

2. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor (show RYK Antibodies) cross-talk in unanchored cells.

3. established mechanism for initiation of CDCP1-mediated signaling; demonstrated that processing of surface CDCP1 by extracellular serine proteases is prerequisite for CDCP1-dependent survival of cancer cells during metastasis; preventing cleavage of CDCP1 abrogated survival signaling associated with CDCP1 and induced PARP1 (show PARP1 Antibodies) cleavage and PARP1 (show PARP1 Antibodies)-mediated apoptosis

4. CDCP1 may have a role in neoplasm metastasis; targeting it with a monoclonal antibody inhibits metastasis in a prostate cancer model